| Literature DB >> 6108711 |
P S Davies, J Rhodes, B Counsell, B K Evans.
Abstract
PRD-92 a well-absorbed mast cell stabilizer was examined in patients with ulcerative colitis by a double-blind controlled trial. Forty-three patients who were in clinical remission or PRD-92 for six months. Relapses occurred in 42% of patients on PRD-92 and 24% on sulfasalazine. PRD-92 has a less prophylactic effect than sulfasalazine in ulcerative colitis.Entities:
Mesh：
Substances：
Year: 1980 PMID： 6108711
Source DB: PubMed Journal: Am J Gastroenterol ISSN： 0002-9270 Impact factor: 10.864